Amit is an entrepreneur turned investor. As a highly-regarded physician, Amit combines practical knowledge across the healthcare value-chain investing as a general partner at Builders VC. He brings entrepreneurial and operational experience as the founder and CMO of Intrinsic Imaging, and advises Arpeggio on funding opportunities and growth challenges.
Amit Mehta, MD, FRCP
Board Director
Builders VC
Joe was the President and CEO of KBI Biopharma from 2002 to 2016, growing the company from 10 employees to 1000+. Joe is currently the President and CEO of Bioventure Partners where he advises early-stage companies like Arpeggio.
Joe McMahon
Strategic Advisor
KBI Biopharma
John started his career at Bristol-Myers Squibb as a group leader of discovery chemistry. Currently, John advises early-stage companies on their medicinal chemistry design and interfaces with CROs to drive fast and accurate preclinical development.
John Dickson, PhD
Medicinal Chemistry
David has served as President & CEO of Lyric Pharmaceuticals, an ICU therapeutic development company which he founded, built and successfully funded, and as CMO and an early employee of Lucid Diagnostics, a medical device-diagnostic company which went public via IPO in 2021.
David Wurtman, MD, MBA
Business Development
Lyric Pharma
Robin Dowell merges genetics and computer science to investigate transcriptional regulation. In an “antedisciplinary” approach, Dr. Dowell ignores boundaries between disciplines to follow this biological problem wherever it leads. Dowell’s background is uniquely diverse; she holds bachelor’s degrees in both genetics and computer engineering from Texas A&M University, and received an M.S. in computer science and Ph.D. in biomedical engineering from Washington University in St. Louis.
Robin Dowell, PhD
BioFrontiers Institute
Scientific Founder
Dave started his career at GSK where he was the VP of Biological Platform Technology and Science, and more recently was the VP of Research Operations at Precision Biosciences. Dave advises Arpeggio on systems biology and our automated drug screening platform.
Dave Morris, PhD
Automation Advisor
GSK
Robert has 24 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol-Myers Squibb and Janssen Pharmaceuticals, part of the Johnson & Johnson group of companies.
Robert Kramer, PhD
Oncology
Portage, BMS, J&J
Bill has led IP for companies like Advanced LiquidLogic, Illumina, and Grail. At Arpeggio, Bill is critical in helping define our patent strategy and portfolio around both our platform and novel chemical entities.
Bill Barrett
WSGR Counsel
Illumina, GRAIL